April SA (APRL.PA)
23 Jun 2017
(The following statement was released by the rating agency) Link to Fitch Ratings' Report: Groupe BPCE - Rating Action Report https://www.fitchratings.com/site/re/898785 PARIS, May 23 (Fitch) Fitch Ratings has affirmed Groupe BPCE's (GBPCE) Long-Term Issuer Default Rating (IDR) at 'A', Short-Term IDR at 'F1' and Viability Rating (VR) at 'a'. The Outlook on the Long-Term IDR is Stable. Fitch has assigned 'A(dcr)' Derivative Counterparty Ratings (DCRs) to BPCE S.A and Natixis, which are notable de
* Reports sales of EUR 227.7 million ($249.0 million), up 9.2 pct at end March 2017
* Swiss drug prices, margins higher than elsewhere in Europe (Recasts headline, first paragraph to highlight Europe's biggest IPO of 2017)
ZURICH, March 24 Galenica expects to raise up to 1.68 billion Swiss francs ($1.70 billion) when it floats its Sante pharmacy business, the Swiss drugmaker said on Friday.
* April delivers 2016 full-year sales of 861.2 million euros ($925.88 million), up 7.9 pct